Core Insights - The core focus of the articles is the announcement by Innovent Biologics regarding the successful completion of the primary endpoint in the Phase III clinical trial DREAMS-3 for its dual-target agonist mazdutide, which targets both GCG and GLP-1 pathways [1][2] Company Summary - Innovent Biologics has developed mazdutide, a dual-target agonist that combines the glucose-lowering and weight-reducing effects of GLP-1 with the energy expenditure benefits of GCG [1] - The DREAMS-3 trial is the first head-to-head Phase III clinical study comparing a GCG/GLP-1 dual-target agonist with the international heavyweight semaglutide in diabetes treatment [1] - The company has completed seven Phase III clinical studies for mazdutide, with several ongoing, including studies focused on obesity and related metabolic conditions [2] Industry Summary - The number of diabetes patients in China has exceeded 140 million and is expected to rise to 174 million by 2045, with an increasing proportion of obesity [2] - Poor blood sugar control can lead to severe complications, making effective weight management alongside glucose control a pressing clinical challenge [2] - There is a significant demand for more effective, safer, and convenient innovative therapies for obesity and its comorbidities in the Chinese market [2]
玛仕度肽DREAMS-3里程碑研究数据读出发布会举行